Analysis of cancer-specific survival in patients with metastatic colorectal cancer: A evidence-based medicine study

Figure 1 Nomogram for predicting the tumor-specific survival of patients with metastatic colorectal cancer. CEA: Carcinoembryonic antigen; CSS: Cancer-specific survival.

Figure 2 Calibration curves based on cancer-specific survival for metastatic colorectal cancer patients. A-C: Calibration curves based on 1-, 2-, and 3-year cancer-specific survival (CSS) of the training cohort; D-F: Calibration curves based on 1-, 2-, and 3-year CSS of the validation cohort.

Figure 3 The nomogram model predicts the clinical decision curve of cancer-specific survival in metastatic colorectal cancer patients. A-C: Clinical decision curves based on 1-, 2-, and 3-year cancer-specific survival (CSS) in the training cohort; D-F: Clinical decision curves based on 1-, 2-, and 3-year CSS in the validation cohort.

Figure 4 X-tile software was used to calculate the optimal truncation value and establish a risk classification system. A and B: The optimal cutoff values of the predicted total scores, including the low-risk group (score: 0-164), medium-risk group (score: 165-247) and high-risk group (score: 248-480); C: Kaplan-Meier curves for different risk levels according to the cancer-specific survival of the training cohort.

Figure 5 Kaplan-Meier survival curves for patients with different risk levels were drawn according to their cancer-specific survival. A: Platoon line; B: Training queue; C: Authentication queue.